Unknown

Dataset Information

0

Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy.


ABSTRACT: PURPOSE:To explore seromarker levels for associations with outcomes in locally advanced pancreatic cancer (LAPC) patients who received chemotherapy and stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS:Serum from LAPC patients in 2 prospective trials of hypofractionated SBRT (5-6.6 Gy × 5) was collected before SBRT. Proximity ligation assay quantified the expression levels of 36 pancreatic cancer-specific candidate seromarkers: Axl, BMP2, CA 125, CA 19-9, CEA, CXCL-1/6/9/10, EGFR, Gas6, Her2, IGF-2, IGFBP-2/3/7, IL-6/6Ra/7/8/12, mesothelin, MMP-1/2/3/7, osteopontin, PDGFRa, PDK1, PF4, RegIV, SPARC, TGF-?, VEGF-A/D, and YKL40. Seromarker values were log transformed owing to log-normal distribution of the values, and Cox regression analysis was performed to assess for any association with overall survival. The Benjamini-Hochberg method was used to control for a false discovery rate (FDR) of only 10%. RESULTS:Sixty-four patients with LAPC were included. No clinical factors (including surgical resection, receipt of pre-SBRT chemotherapy, receipt of post-SBRT chemotherapy, performance status, and age) or potential biomarkers in the panel were associated with improved survival in this cohort after application of the FDR correction. Potential prognostic factors for improved survival for future investigation included surgical resection (P=.007, adjusted P=.153) and the serum expression of IL-8 (P=.006, adjusted P=.153), CA 19-9 (P=.031, adjusted P=.377), and MMP-1 (P=.036, adjusted P=.377). CONCLUSIONS:These data explore the expression of a panel of proteins in pre-SBRT serum of LAPC patients in the context of a conservative FDR correction. None of the clinical factors or expression levels of the serum proteins were found to be associated with survival; however, IL-8, CA 19-9, and MMP-1 were highlighted as possible candidates warranting inclusion in future seromarker studies in the ongoing efforts to identify tools for risk stratification and treatment allocation in LAPC.

SUBMITTER: Rao AD 

PROVIDER: S-EPMC7405990 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy.

Rao Avani D AD   Liu Yufei Y   von Eyben Rie R   Hsu Charles C CC   Hu Chen C   Rosati Lauren M LM   Parekh Arti A   Ng Kendall K   Hacker-Prietz Amy A   Zheng Lei L   Pawlik Timothy M TM   Laheru Daniel A DA   Jaffee Elizabeth M EM   Weiss Matthew J MJ   Le Dung T DT   Hruban Ralph H RH   De Jesus-Acosta Ana A   Wolfgang Christopher L CL   Narang Amol K AK   Chang Daniel T DT   Koong Albert C AC   Herman Joseph M JM  

International journal of radiation oncology, biology, physics 20171012 2


<h4>Purpose</h4>To explore seromarker levels for associations with outcomes in locally advanced pancreatic cancer (LAPC) patients who received chemotherapy and stereotactic body radiation therapy (SBRT).<h4>Methods and materials</h4>Serum from LAPC patients in 2 prospective trials of hypofractionated SBRT (5-6.6 Gy × 5) was collected before SBRT. Proximity ligation assay quantified the expression levels of 36 pancreatic cancer-specific candidate seromarkers: Axl, BMP2, CA 125, CA 19-9, CEA, CXCL  ...[more]

Similar Datasets

| S-EPMC2175362 | biostudies-literature
| S-EPMC6401276 | biostudies-literature
| S-EPMC4319432 | biostudies-literature
| S-EPMC4072613 | biostudies-literature
| S-EPMC6461258 | biostudies-literature
| S-EPMC3713053 | biostudies-other
| S-EPMC9242480 | biostudies-literature
| S-EPMC6139880 | biostudies-literature
| S-EPMC7350078 | biostudies-literature
| S-EPMC9927260 | biostudies-literature